Ambroxol to Slow Progression in Parkinson Disease (ASPro-PD): A Phase IIIA multi-centre randomised placebo-controlled trial

Research summary

This is a phase IIIa,multi-centre,randomised,doubled-blind,parallel-group,placebo-controlled trial,with a 104-week blinded treatment period followed by a 26-week open-label extension. The aim of the trial is to assess whether 1260mg of ambroxol daily can slow down the progression of Parkinson’s disease (PD),in comparison to a matching placebo,and to establish the safety of long-term use of ambroxol at this dose. 330 participants will be recruited from approximately 10 UK sites over a 24-month period. Data analysis will be performed by UCL CCTU’s statisticians at the end of the trial.

Principal Investigator

Prof Michele Hu

Contact us

Email: dendron@ouh.nhs.uk

IRAS number

1008101